Skip to content
OpenCapital
Get started

iRhythm Holdings, Inc. IRTC Acquired in-process research and development

Acquired in-process research and development at other companies

Eli Lilly logo
Eli LillyLLY
——

Other financials

Income statement

See full
Revenue$199.4M+25.7%
Gross profit$141.4M+29.4%
Operating income-$16.2M+50.3%
Net income-$13.9M+54.6%
EPS (diluted)-$0.43+55.7%

Balance sheet

See full
Cash & equivalents$248.5M-35.2%
Total debt$79.0M-10.5%
Total equity$161.2M+86.0%
Total assets$1.0B+8.7%

Cash flow

See full
Operating cash flow-$26.2M-232%
CapEx$6.9M-26.7%
Free cash flow-$33.1M-91.1%

Valuation

See full
Market cap$3.62B+16.0%

Profitability

See full
Gross margin71%+1.6pp
Operating margin-5.5%-2.2pp
Net margin-7.3%-3.1pp
FCF margin2.4%—

Returns & leverage

See full
Return on equity-53.1%-17.4pp
Debt / equity0.5×-0.5×
Current ratio5.2×-0.5×

Where this comes from

Reported directly by iRhythm Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff.

The official record: iRhythm Holdings, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about iRhythm Holdings, Inc. 's acquired in-process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is iRhythm Holdings, Inc. 's acquired in-process research and development?
iRhythm Holdings, Inc. (IRTC) reported acquired in-process research and development of $296K in Q1 2026.
How has iRhythm Holdings, Inc. 's acquired in-process research and development changed year-over-year?
iRhythm Holdings, Inc. 's acquired in-process research and development decreased by 0.0% year-over-year, from $296K to $296K.